A Phase 1/2 interventional study of BMS-986226 and Nivolumab in Cancer, Tumors and Neoplasm, sponsored by Bristol-Myers Squibb. Terminated at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-28.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 80 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
administered intravenously
Drug: BMS-986226 · Biological: Tetanus Vaccine
administered intravenously
Drug: BMS-986226 · Biological: Nivolumab · Biological: Tetanus Vaccine
administered intravenously
Drug: BMS-986226 · Biological: Ipilimumab · Biological: Tetanus Vaccine
specified dose on specified days
specified dose on specified days
Also known as: BMS-936558, PD-1 receptor blocking monoclonal antibody [mAb], Opdivo
specified dose on specified days
Also known as: BMS-734016, MDX010, Checkpoint blocking antibody that recognizes CTLA-4, Yervoy
specified dose on specified days
The Number of Participants Experiencing Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose up to 100 days post last dose, up to approximately 31 months
The Number of Participants Experiencing Serious Adverse Events (SAEs)
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose up to 100 days post last dose, up to approximately 31 months
The Number of Participants Experiencing Adverse Events (AEs) Meeting Dose Limiting Toxicity (DLT) Criteria
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Dose limiting toxicity (DLT) is defined based on the incidence, intensity, and duration of AEs for which no clear alternative cause is identified. The DLT period will be 28 days (4 weeks) in the Preliminary Safety Cohorts. Any toxicities that occur beyond the 4-week DLT period will also be considered in dose-level decisions. For the purpose of participant management, any AE that meets DLT criteria, regardless of the cycle in which it occurs, will lead to discontinuation of study treatment. AEs will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
Time frame: From first dose up to 100 days post last dose, up to approximately 31 months
The Number of Participants Experiencing Adverse Events Leading to Discontinuation
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose up to 100 days post last dose, up to approximately 31 months
The Number of Participants Experiencing Adverse Events Resulting in Death
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose up to 100 days post last dose, up to approximately 31 months
The Number of Participants Experiencing Clinical Laboratory Abnormalities
The number of participants experiencing abnormal laboratory results of Grade 3 or higher. Laboratory values will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 with Grade 3=severe and Grade 4=life threatening.
Time frame: From first dose up to 30 days post last dose (approximately 28 months)
Objective Response Rate (ORR)
ORR is defined as the percentage of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) as assessed by investigator per RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must also have reduction in the short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. BOR for a participant is defined as the best response designation recorded between the date of first dose (or date of randomization) and the date of first objectively documented progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first.
Time frame: From first dose up to documented disease progression, up to 48 months
Median Duration of Response (DOR)
DOR for a participant with confirmed response is defined as the time from the date of first response CR or PR to the date of first objectively documented tumor progression as determined using RECIST v1.1 or death due to any cause, whichever occurs first. Participant who remain alive and have not progressed will be censored on the date of their last tumor assessment. Participants who started subsequent anticancer therapy without a prior reported progression will be censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. CR is defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must also have reduction in the short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose up to the date of the first objectively documented tumor progression or death, whichever occurs first (up to approximately 24 months)
Progression Free Survival (PFS) Rate at 24 Weeks
The PFSR is defined as the Kaplan Meier estimate of percentage of treated participants remaining progression free and surviving at the prespecified timepoint of 24 weeks since the first dosing date. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: The appearance of 1 or more new lesions is also considered progression.)
Time frame: At 24 weeks
Number of Participants With Anti-Drug Antibodies (ADA) for BMS-986226
ADA for BMS-986226 is defined as the number of participants found to have seroconverted or boosted their pre-existing ADA during the study period. Baseline ADA positive is defined as ADA is detected in the last sample before initiation of treatment. ADA positive is defined as 1) an ADA detected (positive seroconversion) sample in a participant for whom ADA is not detected at baseline, or (2) an ADA detected sample with ADA titer to be at least 4-fold or greater (≥) than baseline positive titer.
Time frame: Predose on cycles 1-6, post dose on C1D15, and 30, 60, and 100 days post last dose (up to approximately 31 months)
Changes From Baseline in Cell Surface ICOS Expression on T Cells
Summary measures of changes in Median of Fluorescence of ICOS (MFI) from baseline to the last evaluable time point in cell surface Inducible Costimulator (ICOS) expression on T cells. Baseline = last non missing value prior or on to the first dosing. MFI is a unit for median fluorescence intensity. This unit allows for measurement of relative expression of cell surface markers by a flow cytometer. For the ICOS expression assay, whole blood samples collected from patients on study were incubated with fluorescently labeled antibodies that specifically bind to ICOS. Samples were then analyzed for changes in MFI by flow cytometry. An increase in MFI between patient samples corresponds to an increase in cell surface ICOS expression on target cell subsets.
Time frame: From baseline up to pre-dose and 4 hours post dose on C1D1 and pre-dose and 4 hours post dose on C2D1 (approximately 31 months)
Changes From Baseline in ICOS Ligand+ B Cells
Summary measures of changes in Median of Fluorescence of ICOS (MFI) from baseline to the last evaluable time point in ICOS ligand+ B cells in the tumor and peripheral blood. Baseline = last non missing value prior or on to the first dosing. MFI is a unit for median fluorescence intensity. This unit allows for measurement of relative expression of cell surface markers by a flow cytometer. For the ICOS expression assay, whole blood samples collected from patients on study were incubated with fluorescently labeled antibodies that specifically bind to ICOS. Samples were then analyzed for changes in MFI by flow cytometry. An increase in MFI between patient samples corresponds to an increase in cell surface ICOS expression on target cell subsets.
Time frame: From baseline up to pre-dose and 4 hours post dose on C1D1, 72 hours post dose on C1D4, and pre-dose on C2D1 (approximately 31 months)
Maximum Observed Plasma Concentration (Cmax)
Cmax is the maximum serum concentration that a drug achieves after the drug has been administered and before the administration of a second dose.
Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Effective Elimination Half-Life (T-HALFeff)
Effective elimination half-life that explains the degree of accumulation observed
Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C2D1 and C3D1 (approximately 31 months)
Trough Observed Serum Concentrations (Ctrough)
Trough observed serum concentrations (Ctrough) is defined as the concentration reached by a drug immediately before the next dose is administered
Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C2D1 and C3D1. Pre-dose and 0.5 post dose on C4D1. Pre-dose on C5D1 and C6D1. Pre-dose and 0.5 hours post dose on C7D1. (approximately 31 months)
Time of Maximum Observed Serum Concentration (Tmax)
Tmax is defined as the amount of time that a drug is present at the maximum concentration in serum
Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Area Under Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration [AUC (0-T)]
AUC(0-t) (partial AUC) is defined as the area under the concentration-time curve from dosing (time 0) to time t. AUC(0-t) may be computed for one or more values of t, with specific values of t determined after observing the data.
Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Area Under the Concentration-Time Curve in 1 Dosing Interval [AUC (TAU)]
AUC (TAU) is defined as the area under the plasma concentration-time curve from time zero to the end of the dosing interval
Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Total Body Clearance (CLT)
CLT is defined as the elimination of the drug from the body
Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Average Concentration Over a Dosing Interval (Css-avg)
Css-avg is defined as the average concentration over a dosing interval (AUC\[TAU\]/tau) Note: Coefficient of variation is reported in lieu of geometric coefficient of variation
Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Accumulation Index - Area Under Curve (AI-AUC)
Accumulation Index is defined as the extent of drug accumulation and determined by the ratio of plasma concentration at plateau over plasma concentration after the first dose. The area under curve is defined as the area under the plot of plasma concentration of a drug versus time after dosage which reflects the extent of exposure to a drug and its clearance rate from the body.
Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1, and C3D1 (approximately 31 months)
Accumulation Index - Cmax (AI-Cmax)
Accumulation Index is defined as the extent of drug accumulation and determined by the ratio of plasma concentration at plateau over plasma concentration after the first dose. Cmax is the maximum serum concentration that a drug achieves after the drug has been administered and before the administration of a second dose.
Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1 and C3D1. Pre-dose and 0.5 post dose on C4D1. (Approximately 31 months)
Accumulation Index - Concentrations at the End of Dosing Interval (AI-CTAU)
Accumulation Index is defined as the extent of drug accumulation and determined by the ratio of plasma concentration at plateau over plasma concentration after the first dose.
Time frame: Pre-dose, 0.5, 4, 24, 72, 168, 336, 504 hours post dose on C1D1, C2D1 and C3D1. Pre-dose and 0.5 post dose on C4D1. (Approximately 31 months)
| Milestone | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 7 | 7 | 11 | 9 | 9 | 10 | 12 | 9 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 |
| Not completed | 6 | 7 | 7 | 11 | 9 | 9 | 7 | 11 | 8 |
| Withdrew: Disease progression | 6 | 6 | 7 | 8 | 8 | 7 | 6 | 10 | 6 |
| Withdrew: Adverse event unrelated to study drug | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Study drug toxicity | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Participant request to discontinue study treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| The Number of Participants Experiencing Adverse Events (AEs) | 6 | 7 | 7 | 11 | 9 | 9 | 10 | 12 | 9 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| The Number of Participants Experiencing Serious Adverse Events (SAEs) | 2 | 3 | 2 | 10 | 5 | 9 | 5 | 9 | 5 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Dose limiting toxicity (DLT) is defined based on the incidence, intensity, and duration of AEs for which no clear alternative cause is identified. The DLT period will be 28 days (4 weeks) in the Preliminary Safety Cohorts. Any toxicities that occur beyond the 4-week DLT period will also be considered in dose-level decisions. For the purpose of participant management, any AE that meets DLT criteria, regardless of the cycle in which it occurs, will lead to discontinuation of study treatment. AEs will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
| Participants | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| The Number of Participants Experiencing Adverse Events (AEs) Meeting Dose Limiting Toxicity (DLT) Criteria | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| The Number of Participants Experiencing Adverse Events Leading to Discontinuation | 0 | 0 | 0 | 1 | 1 | 4 | 0 | 3 | 2 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| The Number of Participants Experiencing Adverse Events Resulting in Death | 5 | 3 | 5 | 8 | 5 | 7 | 7 | 8 | 5 |
The number of participants experiencing abnormal laboratory results of Grade 3 or higher. Laboratory values will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 with Grade 3=severe and Grade 4=life threatening.
| Participants | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| HEMOGLOBIN | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 1 | 1 |
| LYMPHOCYTES (ABSOLUTE) | 0 | 1 | 1 | 3 | 2 | 3 | 2 | 4 | 3 |
| LYMPHOCYTES (RELATIVE) | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| ALKALINE PHOSPHATASE | 0 | 0 | 0 | 2 | 1 | 2 | 3 | 2 | 0 |
| ASPARTATE AMINOTRANSFERASE | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
| ALANINE AMINOTRANSFERASE | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
| G-GLUTAMYL TRANSFERASE | 1 | 2 | 1 | 4 | 3 | 2 | 6 | 3 | 1 |
| BILIRUBIN, TOTAL | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| PHOSPHATE | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| LIPASE, TOTAL | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 1 |
| HYPONATREMIA | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| HYPERKALEMIA | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| HYPERGLYCEMIA | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPOKALEMIA | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
ORR is defined as the percentage of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) as assessed by investigator per RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must also have reduction in the short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. BOR for a participant is defined as the best response designation recorded between the date of first dose (or date of randomization) and the date of first objectively documented progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first.
| Percentage of participants | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 0 (0.0 to 45.9) | 0 (0.0 to 41.0) | 0 (0.0 to 41.0) | 0 (0.0 to 28.5) | 0 (0.0 to 33.6) | 0 (0.0 to 33.6) | 0 (0.0 to 30.8) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) |
DOR for a participant with confirmed response is defined as the time from the date of first response CR or PR to the date of first objectively documented tumor progression as determined using RECIST v1.1 or death due to any cause, whichever occurs first. Participant who remain alive and have not progressed will be censored on the date of their last tumor assessment. Participants who started subsequent anticancer therapy without a prior reported progression will be censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. CR is defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must also have reduction in the short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| Months | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Median Duration of Response (DOR) | — | — | — | — | — | — | — | NA (23.4 to 23.4) | — |
The PFSR is defined as the Kaplan Meier estimate of percentage of treated participants remaining progression free and surviving at the prespecified timepoint of 24 weeks since the first dosing date. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: The appearance of 1 or more new lesions is also considered progression.)
| Percentage of participants | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) Rate at 24 Weeks | 16.7 (0.8 to 51.7) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 8.3 (0.5 to 31.1) | 18.8 (1.1 to 53.5) |
ADA for BMS-986226 is defined as the number of participants found to have seroconverted or boosted their pre-existing ADA during the study period. Baseline ADA positive is defined as ADA is detected in the last sample before initiation of treatment. ADA positive is defined as 1) an ADA detected (positive seroconversion) sample in a participant for whom ADA is not detected at baseline, or (2) an ADA detected sample with ADA titer to be at least 4-fold or greater (≥) than baseline positive titer.
| Participants | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Baseline ADA Positive | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| ADA Positive after initiation of treatment | 4 | 6 | 3 | 8 | 4 | 4 | 8 | 9 | 8 |
Summary measures of changes in Median of Fluorescence of ICOS (MFI) from baseline to the last evaluable time point in cell surface Inducible Costimulator (ICOS) expression on T cells. Baseline = last non missing value prior or on to the first dosing. MFI is a unit for median fluorescence intensity. This unit allows for measurement of relative expression of cell surface markers by a flow cytometer. For the ICOS expression assay, whole blood samples collected from patients on study were incubated with fluorescently labeled antibodies that specifically bind to ICOS. Samples were then analyzed for changes in MFI by flow cytometry. An increase in MFI between patient samples corresponds to an increase in cell surface ICOS expression on target cell subsets.
| Median of Fluorescence of ICOS (MFI) | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Baseline Response | 985.5 (554 to 1243) | 659.0 (455 to 775) | 878.0 (599 to 1361) | 482 (197 to 912) | 434.0 (169 to 884) | 634.0 (94 to 1166) | 592.0 (162 to 933) | 714.0 (234 to 1438) | 506.5 (20 to 943) |
| C1D1- Pre-Dose | -394.0 (-394 to 394) | — | — | — | — | -636.0 (-636 to -636) | — | — | — |
| C1D1- 4 hours post dose | -1049.0 (-1049 to -1049) | -603.0 (-603 to -603) | -762.0 (-847 to -565) | -391.0 (-635 to -176) | -324.0 (-481 to -95) | -545.0 (-1029 to -184) | -382.5 (-649 to -116) | -654.5 (-1405 to -214) | -490.0 (-928 to -429) |
| C2D1- Pre-Dose | -421.0 (-729 to -31) | -26.0 (-538 to 104) | -414.0 (-1101 to 630) | -153.0 (-774 to -38) | -185.0 (-865 to -177) | -627.0 (-632 to -622) | -294.0 (-500 to 308) | -185.5 (-1155 to 430) | 11.5 (-104 to 148) |
| C2D1- 4 hours post dose | — | — | — | -167.5 (-229 to -106) | -336.5 (-507 to -166) | -567.0 (-615 to -372) | — | — | -465.5 (-911 to 254) |
Summary measures of changes in Median of Fluorescence of ICOS (MFI) from baseline to the last evaluable time point in ICOS ligand+ B cells in the tumor and peripheral blood. Baseline = last non missing value prior or on to the first dosing. MFI is a unit for median fluorescence intensity. This unit allows for measurement of relative expression of cell surface markers by a flow cytometer. For the ICOS expression assay, whole blood samples collected from patients on study were incubated with fluorescently labeled antibodies that specifically bind to ICOS. Samples were then analyzed for changes in MFI by flow cytometry. An increase in MFI between patient samples corresponds to an increase in cell surface ICOS expression on target cell subsets.
| Median of Fluorescence of ICOS (MFI) | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Baseline Response | -9.0 (-94 to 185) | -33.0 (-70 to 67) | 2.5 (-99 to 95) | 40.5 (-90 to 127) | -60.5 (-171 to 74) | 57.0 (-100 to 182) | -15.0 (-79 to 70) | -11.5 (-113 to 41) | 39.0 (-56 to 103) |
| C1D1 - 4 hours post dose | -106.0 (-106 to -106) | -2.0 (-2 to -2) | -3.0 (-48 to 37) | 1.0 (-9 to 23) | -13.5 (-55 to 0) | 9.5 (-16 to 99) | 3.5 (1 to 6) | 0.0 (-14 to 37) | -6.0 (-21 to 40) |
| C1D4- 72 hours post dose | 11.0 (-181 to 58) | 102.0 (-28 to 190) | 170.0 (118 to 210) | 37.0 (-143 to 231) | 64.5 (-71 to 127) | 29.0 (-106 to 88) | 90.0 (17 to 163) | 70.0 (3 to 143) | 33.5 (-28 to 121) |
| C2D1- Pre dose | -4.0 (-267 to 54) | -24.0 (-211 to 24) | 96.0 (-167 to 207) | -17.0 (-100 to 170) | 103.5 (-39 to 216) | -28.0 (-74 to 18) | -9.0 (-129 to 83) | 61.5 (-20 to 186) | -17.0 (-175 to 103) |
Cmax is the maximum serum concentration that a drug achieves after the drug has been administered and before the administration of a second dose.
| ng/mL | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 733 ± NA | 2250 ± NA | 6609 ± NA | 19524 ± NA | 41698 ± NA | 85905 ± NA | 5440 ± NA | 43309 ± NA | 3451 ± NA |
| C2D1 | — | 1050 ± NA | 7220 ± NA | 23322 ± NA | 45054 ± NA | 91931 ± NA | — | 30200 ± NA | 2697 ± NA |
| C3D1 | — | 1060 ± NA | 3168 ± NA | 15000 ± NA | 41700 ± NA | 76700 ± NA | — | — | 3880 ± NA |
Effective elimination half-life that explains the degree of accumulation observed
| Hours | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| C2D1 | — | — | — | 212 ± 9.4 | 102 ± NA | — | — | — | — |
| C3D1 | — | — | — | — | 308 ± NA | — | — | — | — |
Trough observed serum concentrations (Ctrough) is defined as the concentration reached by a drug immediately before the next dose is administered
| ng/mL | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | — | 12.5 ± NA | 27.0 ± NA | 943 ± 584.4 | 1501 ± 1202.9 | 1491 ± 1287.3 | 12.5 ± NA | — | 12.5 ± NA |
| Cycle 3 Day 1 | — | 12.5 ± NA | 27.2 ± 20.72 | 892 ± NA | 180 ± NA | 3150 ± NA | 12.5 ± NA | — | 12.5 ± NA |
| Cycle 4 Day 1 | 12.5 ± NA | — | 12.5 ± NA | 504 ± NA | 800 ± 401.1 | — | 12.5 ± NA | — | 12.5 ± NA |
| Cycle 5 Day 1 | 12.5 ± NA | — | — | — | 3300 ± NA | — | — | — | 12.5 ± NA |
| Cycle 6 Day 1 | 12.5 ± NA | — | — | — | — | — | — | — | — |
| Cycle 7 Day 1 | — | — | — | — | — | — | — | 12.5 ± NA | 12.5 ± NA |
Tmax is defined as the amount of time that a drug is present at the maximum concentration in serum
| Hours | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 4.00 (0.067 to 4.22) | 0.283 (0.133 to 4.00) | 0.534 (0.467 to 4.50) | 1.25 (0.467 to 21.7) | 3.88 (0.467 to 24.0) | 4.00 (0.500 to 24.0) | 2.88 (0.467 to 4.50) | 1.02 (0.483 to 18.9) | 0.600 (0.467 to 22.0) |
| C2D1 | — | 0.600 (0.600 to 0.600) | 0.967 (0.967 to 0.967) | 4.00 (0.483 to 4.00) | 1.00 (0.433 to 4.52) | 4.00 (0.383 to 4.00) | — | 2.83 (2.83 to 2.83) | 2.24 (0.483 to 4.00) |
| C3D1 | — | 0.133 (0.133 to 0.133) | 0.534 (0.517 to 0.550) | 0.467 (0.467 to 0.467) | 1.03 (1.03 to 1.03) | 0.967 (0.967 to 0.967) | — | — | 0.500 (0.500 to 0.500) |
AUC(0-t) (partial AUC) is defined as the area under the concentration-time curve from dosing (time 0) to time t. AUC(0-t) may be computed for one or more values of t, with specific values of t determined after observing the data.
| h*ng/mL | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 33704 ± NA | 175228 ± NA | 682168 ± NA | 1951486 ± NA | 4966612 ± NA | 8346408 ± NA | 370356 ± NA | 4805561 ± NA | 277927 ± NA |
| C2D1 | — | 13921 ± NA | 933038 ± NA | 3534177 ± NA | 5887547 ± NA | 4070442 ± NA | — | 2528949 ± NA | 35464 ± NA |
| C3D1 | — | 18442 ± NA | 81982 ± NA | 2727643 ± NA | 5157593 ± NA | 7511434 ± NA | — | — | 55178 ± NA |
AUC (TAU) is defined as the area under the plasma concentration-time curve from time zero to the end of the dosing interval
| h*ng/mL | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 37392 ± NA | 189031 ± NA | 704072 ± NA | 1992589 ± NA | 5148217 ± NA | 8740936 ± NA | 404651 ± NA | 5006775 ± NA | 301365 ± NA |
| C2D1 | — | — | 933038 ± NA | 3693517 ± NA | 5766681 ± NA | 10833374 ± NA | — | — | — |
| C3D1 | — | 19007 ± NA | 373429 ± NA | 2727643 ± NA | 5157593 ± NA | — | — | — | — |
CLT is defined as the elimination of the drug from the body
| mL/h | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| C2D1 | — | — | 26.8 ± NA | 21.7 ± NA | 34.7 ± NA | 36.9 ± NA | — | — | — |
| C3D1 | — | 421 ± NA | — | 29.3 ± NA | 38.8 ± NA | — | — | — | — |
Css-avg is defined as the average concentration over a dosing interval (AUC\[TAU\]/tau) Note: Coefficient of variation is reported in lieu of geometric coefficient of variation
| ng/mL | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| C2D1 | — | — | 1397 ± NA | 5499 ± NA | 8581 ± NA | 16115 ± NA | — | — | — |
| C3D1 | — | 28.3 ± NA | 556 ± NA | 4065 ± NA | 7666 ± NA | — | — | — | — |
Accumulation Index is defined as the extent of drug accumulation and determined by the ratio of plasma concentration at plateau over plasma concentration after the first dose. The area under curve is defined as the area under the plot of plasma concentration of a drug versus time after dosage which reflects the extent of exposure to a drug and its clearance rate from the body.
| Ratio | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| C2D1 | — | — | — | 1.07 ± NA | 0.856 ± NA | 0.953 ± NA | — | — | — |
| C3D1 | — | 0.100 ± NA | — | 0.808 ± NA | 1.28 ± NA | — | — | — | — |
Accumulation Index is defined as the extent of drug accumulation and determined by the ratio of plasma concentration at plateau over plasma concentration after the first dose. Cmax is the maximum serum concentration that a drug achieves after the drug has been administered and before the administration of a second dose.
| Ratio | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| C2D1 | — | 0.475 ± NA | — | 1.19 ± NA | 0.951 ± NA | 0.861 ± NA | — | — | 0.687 ± 23 |
| C3D1 | — | 0.457 ± NA | 0.309 ± NA | 0.920 ± NA | 1.11 ± NA | 0.940 ± NA | — | — | 1.11 ± NA |
| C4D1 | — | — | — | — | — | — | — | 0.633 ± NA | — |
Accumulation Index is defined as the extent of drug accumulation and determined by the ratio of plasma concentration at plateau over plasma concentration after the first dose.
| Ratio | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| C2D1 | — | — | — | 0.640 ± NA | 1.12 ± NA | 1.38 ± NA | — | — | — |
| C3D1 | — | NA ± NA | — | 0.391 ± NA | 33.3 ± NA | — | — | — | — |
Collected over Participants were assessed for all-cause mortality from their enrollment to study completion, (up to approximately 50 months). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 31 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Preliminary - BMS-986226 2 mg | 5/6 (83.3%) | 2/6 (33.3%) | 6/6 (100%) |
| Preliminary - BMS-986226 8 mg | 3/7 (42.9%) | 3/7 (42.9%) | 7/7 (100%) |
| Part A - BMS-986226 25 mg | 5/7 (71.4%) | 2/7 (28.6%) | 7/7 (100%) |
| Part A - BMS-986226 80 mg | 8/11 (72.7%) | 10/11 (90.9%) | 10/11 (90.9%) |
| Part A - BMS-986226 200 mg | 5/9 (55.6%) | 5/9 (55.6%) | 9/9 (100%) |
| Part A - BMS-986226 400 mg | 7/9 (77.8%) | 9/9 (100%) | 9/9 (100%) |
| Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | 7/10 (70%) | 5/10 (50%) | 10/10 (100%) |
| Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | 8/12 (66.7%) | 9/12 (75%) | 12/12 (100%) |
| Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | 5/9 (55.6%) | 5/9 (55.6%) | 9/9 (100%) |
| Total | 53/80 (66.3%) | 50/80 (62.5%) | 79/80 (98.8%) |
| Event | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 | 2/7 | 0/7 | 5/11 | 4/9 | 6/9 | 5/10 | 6/12 | 4/9 | 33/80 |
| Intestinal obstructionGastrointestinal disorders | 0/6 | 0/7 | 0/7 | 1/11 | 0/9 | 2/9 | 0/10 | 0/12 | 0/9 | 3/80 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/7 | 0/7 | 2/11 | 0/9 | 1/9 | 1/10 | 0/12 | 0/9 | 4/80 |
| PyrexiaGeneral disorders | 1/6 | 0/7 | 0/7 | 0/11 | 0/9 | 0/9 | 0/10 | 0/12 | 0/9 | 1/80 |
| Tumour associated feverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 | 0/7 | 0/7 | 0/11 | 0/9 | 0/9 | 0/10 | 0/12 | 0/9 | 1/80 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/6 | 0/7 | 0/7 | 0/11 | 0/9 | 0/9 | 0/10 | 0/12 | 0/9 | 1/80 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/6 | 0/7 | 0/7 | 0/11 | 0/9 | 0/9 | 0/10 | 2/12 | 0/9 | 2/80 |
| Rectal haemorrhageGastrointestinal disorders | 0/6 | 1/7 | 0/7 | 1/11 | 0/9 | 0/9 | 0/10 | 0/12 | 0/9 | 2/80 |
| Blood bilirubin increasedInvestigations | 0/6 | 0/7 | 1/7 | 0/11 | 0/9 | 0/9 | 0/10 | 0/12 | 1/9 | 2/80 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/7 | 1/7 | 0/11 | 0/9 | 0/9 | 0/10 | 0/12 | 0/9 | 1/80 |
| Event | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 0/6 | 3/7 | 3/7 | 5/11 | 8/9 | 8/9 | 4/10 | 6/12 | 3/9 | 40/80 |
| NauseaGastrointestinal disorders | 1/6 | 2/7 | 0/7 | 1/11 | 0/9 | 6/9 | 3/10 | 3/12 | 0/9 | 16/80 |
| FatigueGeneral disorders | 2/6 | 1/7 | 1/7 | 4/11 | 3/9 | 5/9 | 3/10 | 5/12 | 1/9 | 25/80 |
| Decreased appetiteMetabolism and nutrition disorders | 1/6 | 1/7 | 1/7 | 2/11 | 0/9 | 5/9 | 2/10 | 3/12 | 0/9 | 15/80 |
| DiarrhoeaGastrointestinal disorders | 2/6 | 0/7 | 0/7 | 3/11 | 0/9 | 4/9 | 1/10 | 1/12 | 0/9 | 11/80 |
| Aspartate aminotransferase increasedInvestigations | 1/6 | 3/7 | 0/7 | 2/11 | 1/9 | 0/9 | 4/10 | 3/12 | 1/9 | 15/80 |
| AnaemiaBlood and lymphatic system disorders | 1/6 | 0/7 | 0/7 | 3/11 | 1/9 | 3/9 | 2/10 | 4/12 | 0/9 | 14/80 |
| VomitingGastrointestinal disorders | 1/6 | 1/7 | 0/7 | 0/11 | 2/9 | 2/9 | 1/10 | 4/12 | 3/9 | 14/80 |
| PyrexiaGeneral disorders | 0/6 | 1/7 | 1/7 | 1/11 | 1/9 | 3/9 | 2/10 | 1/12 | 0/9 | 10/80 |
| Blood creatinine increasedInvestigations | 0/6 | 0/7 | 0/7 | 0/11 | 0/9 | 3/9 | 0/10 | 3/12 | 0/9 | 6/80 |
| Age, Continuous(Years) | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 59.3 ± 10.4 | 58.3 ± 7.8 | 63.6 ± 12.3 | 62.5 ± 9.7 | 55.3 ± 15.9 | 61.7 ± 16.9 | 55.7 ± 9.6 | 62.3 ± 11.7 | 58.3 ± 7.1 | 59.7 ± 11.5 |
| Sex: Female, Male(Participants) | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 3 | 5 | 3 | 3 | 4 | 5 | 2 | 28 |
| Male | 5 | 5 | 4 | 6 | 6 | 6 | 6 | 7 | 7 | 52 |
| Ethnicity (NIH/OMB)(Participants) | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 6 |
| Not Hispanic or Latino | 5 | 5 | 4 | 5 | 4 | 2 | 6 | 8 | 5 | 44 |
| Unknown or Not Reported | 0 | 1 | 2 | 6 | 5 | 6 | 3 | 4 | 3 | 30 |
| Race (NIH/OMB)(Participants) | Preliminary - BMS-986226 2 mg | Preliminary - BMS-986226 8 mg | Part A - BMS-986226 25 mg | Part A - BMS-986226 80 mg | Part A - BMS-986226 200 mg | Part A - BMS-986226 400 mg | Part C1 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Part C1 - BMS-986226 200 mg + Ipilimumab 3 mg/kg | Part C2 - BMS-986226 25 mg + Ipilimumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 |
| White | 4 | 6 | 6 | 10 | 9 | 9 | 7 | 12 | 6 | 69 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 1 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2017 to primary completion in Dec 2021, 51 months.
Results were first posted in Feb 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.